◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › H › HALO

Halozyme Therapeutics Inc (HALO) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-19

Halozyme Therapeutics Inc (HALO) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 423 employees. Its market capitalization is roughly $13 billion. In the fiscal year ended 2025-12-31, HALO reported $1.4B in revenue and $317M in net income.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.

Interactive charts & full statements → Open the HALO valuation workbench →

HALO Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$1.7B	$1.4B	$1.0B	$829M	$660M	$443M	$268M	$196M	$152M	$317M	$147M	$135M	$75M	$55M	$42M	$56M	$14M	$14M	$9M	$4M	$1M
Gross Profit	$1.3B	$1.1B	$856M	$637M	$521M	$362M	$224M	$150M	$142M	$285M	$113M	$106M	$53M	$49M	$41M	$56M	$13M	$13M	$8M	$4M	$1M
Gross Margin %	78.2%	78.1%	84.3%	76.8%	78.9%	81.6%	83.8%	76.8%	93.3%	90.2%	77.4%	78.3%	69.8%	88.6%	97.4%	99.5%	92.8%	97.7%	96.2%	93.7%	55.5%
Operating Income (EBIT)	$945M	$816M	$551M	$338M	$268M	$276M	$144M	($68M)	($69M)	$81M	($83M)	($27M)	($63M)	($80M)	($54M)	($20M)	($54M)	($58M)	($50M)	($28M)	($16M)
Operating Margin %	56.8%	58.5%	54.3%	40.7%	40.5%	62.2%	53.9%	-34.5%	-45.6%	25.6%	-56.7%	-20.3%	-83.7%	-146.8%	-126.7%	-35.4%	-398.2%	-427.6%	-575.5%	-740.9%	-1587.3%
Net Income	$413M	$317M	$444M	$282M	$202M	$403M	$129M	($72M)	($80M)	$63M	($103M)	($32M)	($68M)	($83M)	($54M)	($20M)	($53M)	($58M)	($49M)	($24M)	($15M)
Net Margin %	24.8%	22.7%	43.7%	34.0%	30.6%	90.8%	48.2%	-36.9%	-52.9%	19.9%	-70.2%	-23.9%	-90.8%	-152.3%	-126.5%	-35.2%	-390.8%	-426.9%	-555.1%	-628.9%	-1502.6%
EBITDA	—	$573M	$657M	$452M	$316M	$279M	$148M	($64M)	($67M)	$83M	($81M)	($26M)	($61M)	($79M)	($53M)	($19M)	($53M)	($57M)	($49M)	($28M)	($15M)
Earnings Per Share (EPS)	$3.35	$2.56	$3.43	$2.10	$1.44	$2.74	$0.91	$-0.50	$-0.56	$0.45	$-0.81	$-0.25	$-0.56	$-0.74	$-0.48	$-0.19	$-0.56	$-0.67	$-0.61	$-0.32	$-0.24
Shares Outstanding (M)	—	124M	129M	134M	141M	147M	141M	144M	144M	139M	128M	127M	123M	113M	111M	103M	94M	87M	80M	74M	63M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HALO Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$481M	$377M	$452M	$354M	$326M	$265M	$298M	$290M	$231M
Gross Profit	$402M	$268M	$350M	$281M	$262M	$199M	$256M	$241M	$174M
Gross Margin %	83.6%	71.1%	77.4%	79.4%	80.3%	75.0%	85.9%	83.0%	75.2%
Operating Income (EBIT)	$288M	$185M	$254M	$218M	$202M	$142M	$176M	$163M	$117M
Operating Margin %	59.9%	49.0%	56.3%	61.5%	62.2%	53.4%	58.9%	56.3%	50.7%
Net Income	$230M	$150M	($142M)	$175M	$165M	$118M	$137M	$137M	$93M
Net Margin %	47.8%	39.8%	-31.3%	49.5%	50.7%	44.6%	46.0%	47.2%	40.3%
EBITDA	—	$220M	($69M)	$244M	$230M	$169M	$203M	$190M	$143M
Earnings Per Share (EPS)	$1.90	$1.22	$-1.20	$1.43	$1.33	$0.93	$1.06	$1.05	$0.72
Shares Outstanding (M)	—	123M	118M	122M	124M	127M	129M	130M	129M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HALO Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$819M	$652M	$479M	$389M	$240M	$299M	$55M	($85M)	($50M)	$134M	($50M)	($37M)	($48M)	($49M)	($64M)	($34M)	($45M)	($40M)	($35M)	$0M	$7M
Capital Expenditures (CapEx)	$12M	$7M	$11M	$15M	$5M	$1M	$3M	$4M	$5M	$1M	$3M	$2M	$1M	$2M	$1M	$1M	$1M	$1M	$1M	$2M	$0M
Free Cash Flow (FCF)	$807M	$645M	$468M	$373M	$235M	$298M	$53M	($89M)	($54M)	$133M	($54M)	($39M)	($49M)	($52M)	($66M)	($35M)	($46M)	($42M)	($37M)	($3M)	$7M
FCF Margin %	48.5%	46.2%	46.1%	45.0%	35.6%	67.2%	19.8%	-45.6%	-35.7%	41.9%	-36.5%	-29.2%	-64.9%	-94.2%	-155.3%	-62.7%	-337.9%	-304.3%	-416.8%	-66.1%	684.0%
Dividends Paid	—	—	—	$13M	—	$13M	$63M	$14M	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HALO Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$241M	$180M	$219M	$179M	$100M	$154M	$178M	$115M	$56M
Capital Expenditures (CapEx)	$4M	$4M	$1M	$3M	$2M	$1M	$3M	$2M	$3M
Free Cash Flow (FCF)	$237M	$176M	$218M	$176M	$98M	$153M	$175M	$114M	$53M
FCF Margin %	49.3%	46.8%	48.2%	49.6%	30.1%	57.9%	58.9%	39.2%	23.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HALO Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$2.6B	$2.5B	$2.1B	$1.7B	$1.8B	$1.1B	$580M	$566M	$440M	$520M	$262M	$182M	$166M	$102M	$135M	$66M	$91M	$77M	$77M	$103M	$46M
Cash & Cash Equivalents	$163M	$134M	$116M	$118M	$234M	$119M	$148M	$120M	$58M	$169M	$67M	$43M	$61M	$27M	$100M	$53M	$83M	$67M	$64M	$98M	$44M
Total Liabilities	$2.4B	$2.5B	$1.7B	$1.6B	$1.7B	$907M	$429M	$474M	$191M	$312M	$294M	$139M	$125M	$122M	$86M	$55M	$71M	$70M	$61M	$46M	$23M
Total Debt (Short + Long-Term)	$2.1B	$2.1B	$1.5B	$1.5B	$1.5B	$877M	$397M	$403M	$126M	$202M	$217M	$50M	$100M	$50M	$30M	$0M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$144M	$49M	$364M	$84M	$170M	$197M	$151M	$92M	$249M	$208M	($32M)	$43M	$41M	($20M)	$49M	$11M	$20M	$7M	$15M	$58M	$23M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive HALO viewer.

HALO Metric Deep Dives

Other Companies in BIOTECHNOLOGY

ASND · Ascendis Pharma AS — $16 billion
EXEL · Exelixis Inc — $14 billion
SMMT · Summit Therapeutics PLC — $14 billion
BBIO · BridgeBio Pharma Inc — $13 billion
BMRN · Biomarin Pharmaceutical Inc — $12 billion
MDGL · Madrigal Pharmaceuticals Inc — $12 billion
CORT · Corcept Therapeutics Incorporated — $12 billion
AXSM · Axsome Therapeutics Inc — $11 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← HALEOSLABS All “H” companies HALX →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.